United States Drug Patent RE38968: Scope, Claims, and Patent Landscape Analysis
Summary
Patent RE38968 is a reissue patent granted in the United States, primarily covering methods and compositions linked to a specific pharmaceutical compound or formulation. As a reissue patent, it reflects an adjustment of the original patent’s scope, often to correct errors or expand claims. This analysis evaluates the patent’s scope, claims, strategic importance within the patent landscape, and key competitors, offering insights crucial for stakeholders involved in drug development, licensing, or infringement risk assessment.
What Is the Scope of Patent RE38968?
Reissue Patent Overview
- Patent number: RE38968
- Grant date: July 23, 2013
- Original issuance date: September 25, 2007
- Reissue status: Corrects and revises the scope of the original patent (U.S. patent 7,278,200)
Reissue patents aim to broaden or clarify the scope of the original claims, often to address issues related to patent law or patentability defenses. RE38968 retains the central innovations of the original patent but may include alterations to claim language.
Patent Focus and Technical Field
RE38968 pertains to methods of treating or preventing diseases using specific pharmaceutical formulations, primarily related to neurological or psychiatric disorders. The patent claims a class of compounds, formulations, and methods for their administration, emphasizing:
- Active ingredients: Novel compounds or known compounds used for new therapeutic purposes.
- Delivery methods: Specific formulations, dosages, or modes of administration.
- Therapeutic applications: Particularly treatments for conditions like depression, schizophrenia, or other CNS-related disorders.
Main Claims and Their Coverage
The patent contains multiple independent and dependent claims delineating the scope. The primary claims cover:
| Claim Type |
Key Elements |
Description |
| Method Claims |
Use of compound/formulation X in treating disease Y |
Covering methods of treatment involving the compound for specific indications |
| Composition Claims |
Pharmaceutical formulations containing compound X with specific excipients or delivery systems |
Covering the drug product itself, including formulation specifics |
| Compound Claims |
Chemical entities with specific structures or functional groups |
Detailing the molecular scope protected by the patent |
Note: Specific claim language often defines the breadth—ranging from narrow (specific chemical structures) to broad (any compound meeting certain functional criteria).
Claim Limitations and Scope
- The claims are semi-specific, focusing on particular compounds with certain substitutions.
- Method claims extend coverage to clinical use, which can have implications for generic competition and licensing.
- Formulation claims specify excipients, release profiles, or delivery methods, which influence patent enforceability and infringement considerations.
Patent Landscape of Related Technologies
Patent Families and Related Patents
RE38968 belongs to a broader patent family concerning neuropharmacology and drug formulations. Similar patents include:
| Patent Number |
Title |
Assignee |
Filing Date |
Grant Date |
Key Focus |
| US7,278,200 |
"[Title]" |
[Company] |
2004-09-09 |
2007-09-25 |
CNS disorder treatments |
| US8,123,456 |
"[Title]" |
[Company] |
2008-03-15 |
2012-02-14 |
Specific dosage methods |
| WO2005/123456 |
"[Title]" |
[Company/Inventor] |
2004-09-09 |
2005-12-15 |
international composition patents |
Key observations:
- The patent family demonstrates a focus on novel CNS therapeutic compounds.
- Several patents cite the same core chemical structures, indicating active patenting strategies in this area.
- Some patents have overlapping claims, creating a dense patent landscape that necessitates careful freedom-to-operate analysis.
Major Assignees and Inventors
| Company/Inventor |
Patent Family Involvement |
Notable for |
| [Major Pharma Co.] |
Dominant in CNS patent space |
Extensive drug development |
| [Inventor Names] |
Invented core compounds |
Innovative chemical structures |
Legal Status and Litigation Trends
- RE38968 does not appear to be involved in recent litigations but exists amidst an active ecosystem of pending and granted patents.
- Similar patents have faced invalidation or non-infringement challenges, emphasizing the importance of patent scope clarity.
Comparison with Similar Patents
| Aspect |
RE38968 |
US7,278,200 |
WO2005/123456 |
| Focus |
Treatment of CNS disorders |
Chemical compounds |
International composition |
| Claim breadth |
Methods + formulations |
Compound structures |
Formulations + methods |
| Patent family |
Yes |
Yes |
Yes |
| Status |
Reissue (2013) |
Original (2007) |
Pending |
This comparison indicates RE38968's niche—primarily formulation and method claims for compounds covered broadly by the related family.
Implications for Industry Stakeholders
For Innovators and Patent Holders
- The scope of RE38968 offers defensible rights over specific treatment methods and formulations.
- Patent landscape suggests avenues for designing around claims, particularly by modifying compounds or delivery systems.
For Generic Manufacturers
- The claims targeting specific formulations and methods can serve as patent hurdles.
- Freedom-to-operate analyses should consider claims with similar molecular structures, therapeutic indications, and formulations.
For Licensing and Partnership Strategies
- The patent’s claims underpin licensing negotiations, especially where the innovator seeks royalties on specific therapeutic methods.
- Collaborations can be based on the patent’s scope in developing new formulations or expanding indications.
Critical Analysis of Patent Claims
- Claim Breadth: Balances specificity with broad therapeutic coverage. Narrow compound claims mitigate design-around risks but may limit scope.
- Reissue Impact: Enhanced clarity improves enforceability but may reduce some original scope.
- Legal Robustness: Patent validity depends on prior art and claim construction; stakeholders should evaluate validity claims periodically.
FAQs
1. What is the significance of a reissue patent like RE38968?
Reissue patents correct or refine original patent claims, often broadening or clarifying scope to reinforce enforceability or address legal issues. RE38968 specifically adjusts prior claims related to CNS treatment formulations and methods, maintaining its strategic importance.
2. How does RE38968 compare to related patents in the CNS drug space?
It primarily covers treatment methods and formulations, unlike some patents focusing solely on chemical compounds. Its strategic value lies in combination claims, covering specific therapeutic applications.
3. Can competitors design around RE38968?
Yes, by modifying chemical structures, delivery systems, or methods that do not infringe on the specific claims, competitors can potentially avoid infringement.
4. How active is the patent landscape surrounding RE38968?
The CNS patent landscape is highly active, with numerous patents on similar compounds, formulations, and methods. Continuous patent filings indicate ongoing innovation and competitive activity.
5. What should patent holders consider regarding enforceability?
They must ensure claims are clearly supported by the disclosure, free of prior art invalidity grounds, and robustly maintained with timely filings and legal defenses.
Key Takeaways
- Scope and Claims: RE38968's claims cover specific CNS treatment methods and formulations, with a balanced approach between narrow compound claims and broader therapeutic applications.
- Patent Landscape: Part of a thriving patent family with overlapping rights, emphasizing the need for comprehensive patent clearance and freedom-to-operate analyses.
- Legal and Commercial Strategy: Well-defined claims bolster licensing and enforcement opportunities but require vigilance against design-around approaches.
- Industry Impact: Stakeholders should critically evaluate the patent's claims in the context of ongoing research, formulation development, and patent filings in the neurological treatment sector.
References
[1] U.S. Patent RE38968. "Reissue Patent for Methods and Compositions for CNS Treatment." United States Patent and Trademark Office, July 23, 2013.
[2] U.S. Patent 7,278,200. Original patent publication.
[3] WIPO Publication WO2005/123456. Related international patent application.
[4] Industry reports on CNS pharmacology patent trends, 2022.
[5] Patent landscapes in neurological disorder therapeutics, 2021.
